Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
NCT03262922 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 327
Last updated 2022-04-04
Summary
The aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.
Conditions
- Systemic Scleroderma
Sponsors & Collaborators
-
Rennes University Hospital
lead OTHER
Principal Investigators
-
Patrick JEGO, Pr · Rennes University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-29
- Primary Completion
- 2019-12-31
- Completion
- 2022-02-18
Countries
- France
Study Locations
More Related Trials
-
Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis
NCT03271320 ·Status: COMPLETED
-
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226 ·Status: RECRUITING ·Phase: NA
-
Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis
NCT00843102 ·Status: COMPLETED
-
Lower Urinary Tract Symptoms in Systemic Sclerosis
NCT01971294 ·Status: COMPLETED
-
Systemic Sclerosis Clinical and Biomarker Study
NCT02531009 ·Status: WITHDRAWN
-
Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?
NCT05482594 ·Status: UNKNOWN
-
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
NCT07015060 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
NCT02480335 ·Status: COMPLETED ·Phase: PHASE4
-
Pragmatic Clinical Trials in Scleroderma
NCT03610217 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Calcinosis in Systemic Sclerosis
NCT03340194 ·Status: COMPLETED
-
Optical Coherence Tomography Imaging in Systemic Sclerosis
NCT04532151 ·Status: COMPLETED ·Phase: NA
-
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
NCT02212249 ·Status: COMPLETED ·Phase: NA
-
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
NCT02887495 ·Status: COMPLETED
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles
NCT07298551 ·Status: NOT_YET_RECRUITING
-
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pilot Study of Description of Cicatrisation Rates of Digital Ulcers in Systemic Scleroderma
NCT04319120 ·Status: RECRUITING
-
Effect of Bosentan in Scleroderma Renal Crisis
NCT01241383 ·Status: COMPLETED ·Phase: PHASE2
-
Development and Prevention of Severe Heart Disease in Systemic Sclerosis
NCT01829126 ·Status: UNKNOWN
-
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
NCT05171114 ·Status: COMPLETED ·Phase: NA
-
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06167408 ·Status: COMPLETED
-
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
NCT00706082 ·Status: TERMINATED
-
Trichoscopy and Systemic Scleroderma
NCT04804930 ·Status: RECRUITING
-
Assessment of Nutritional Status in Systemic Sclerosis
NCT04301596 ·Status: UNKNOWN
-
Fresolimumab In Systemic Sclerosis
NCT01284322 ·Status: COMPLETED ·Phase: PHASE1